Scarica l'app Stockscreener
55.05
1.42%
0.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol-Myers Squibb Cancer And AI Deals Put Valuation In Focus - simplywall.st
Citi Raises Bristol-Myers (BMY) Target as Sector Outlook Improves into 2026 - Finviz
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - TradingView
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo - Endpoints News
How Covington’s Dargan Led $18 Billion in Bristol Myers Deals - Bloomberg Law News
A Look At Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum - simplywall.st
Bristol Myers moves SC to stop Zydus from selling biosimilar cancer drug - The Economic Times
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for - Finviz
Ruffer LLP Invests $6.84 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Stock Position Increased by Mirae Asset Global Investments Co. Ltd. - MarketBeat
AustralianSuper Pty Ltd Lowers Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb (BMY) Pricing Reflect Its Fundamentals After A Steady Share Performance - simplywall.st
Bristol Myers Squibb (BMY), Microsoft (MSFT) Partner to Enhance Early Lung Cancer Detection Through AI - Finviz
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
P/E Ratio Insights for Bristol-Myers SquibbBristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol-Myers Squibb (BMY) Sees Price Target Raised by Piper San - GuruFocus
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37 - 富途牛牛
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion - BioSpace
General Motors To Rally More Than 27%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board - GuruFocus
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $60 - 富途牛牛
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - Yahoo Finance
Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout - Chartmill
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle - Benzinga
Bristol-Myers Squibb Stock Outlook: Is Wall Street Bullish or Bearish? - Yahoo Finance
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy - Finviz
Bristol-Myers Squibb (BMY) Leads Record Lobbying Surge in Health - GuruFocus
Bristol-Myers Squibb Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) - Benzinga
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $60 - 富途牛牛
Bristol-Myers Squibb (BMY) Stock Analysis: Evaluating the 4.61% Dividend Yield and Growth Outlook - DirectorsTalk Interviews
What the Options Market Tells Us About Bristol-Myers Squibb - Benzinga
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Sold by Quilter Plc - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb: The Rerating Was FastThe Proof Will Be Slow (Rating Downgrade) - Seeking Alpha
AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. - Finviz
Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments - Yahoo Finance
Bristol Myers Squibb and Janux Launch Partnership on Tumor-Activated T Cell Engagers - Oncodaily
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - Finviz
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results - Yahoo Finance
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
BMS snags top neuro researcher from Eisai—Chutes & Ladders - Fierce Biotech
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Did AI Lung Imaging And New HCM Data Just Shift Bristol Myers Squibb’s (BMY) Investment Narrative? - simplywall.st
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Nigeria
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Pharmaceutical Technology
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com South Africa
Janux stock rises after Bristol Myers Squibb collaboration deal - Investing.com
Is BMY's Deep Pipeline the Key to Its Next Growth Phase? - Yahoo Finance
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech
Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb - marketscreener.com
Janux, Bristol Myers Squibb partner on tumor-activated therapy - Investing.com
Janux Therapeutics stock soars after Bristol Myers Squibb collaboration - Investing.com
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer - marketscreener.com
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Yahoo Finance
Hepatitis Therapeutics Market Overview and Leading Players: - openPR.com
Bristol Myers Squibb teams up with Microsoft for AI-powered lung cancer detection - Mugglehead Magazine
Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal - Law360
Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery - Insider Monkey
1.82%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):